Sonia Varghese, MD
Hematology & Oncology · Oklahoma City, OKNPI 1396065405
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,906 of the $2,703 with a category attached, or 70.5%. 32 manufacturers reported payments, led by Pfizer at 34.4% of the total. Reporting peaked in 2022 at $1,135 and has fallen 93.7% since, to $71 in 2025. That places this record below the midpoint for hematology & oncology clinicians in OK, where the typical reported total is $2,658.
Across 162 payments — averaging $16.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$930
- Novartis$433
- Genentech USA, Inc.$147
- E.r. Squibb & Sons, L.L.C.$147
- Merck$119
- AbbVie$98
- plus $829 from 26 others
Across 45 payments — averaging $6486.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$213K
- Novartis$32K
- Macrogenics, Inc.$27K
- EMD Serono, Inc.$19K
What the payments were for
- Food & beverage$1,90671%
- Education$79729%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 58 | $930 |
| Novartis | 25 | $433 |
| Genentech USA, Inc. | 9 | $147 |
| E.r. Squibb & Sons, L.L.C. | 8 | $147 |
| Merck | 8 | $119 |
| AbbVie | 6 | $98 |
| AstraZeneca(2 entities) | 4 | $88 |
| Daiichi Sankyo Inc. | 3 | $59 |
| Incyte Corporation | 3 | $56 |
| Bristol Myers Squibb | 3 | $56 |
| EMD Serono, Inc. | 3 | $50 |
| Sanofi | 2 | $50 |
| Ipsen Biopharmaceuticals, Inc | 3 | $49 |
| G1 Therapeutics, Inc. | 3 | $44 |
| Astellas Pharma US Inc | 3 | $39 |
| Eisai Inc. | 2 | $38 |
| Sobi, Inc | 2 | $33 |
| Emmaus Medical, Inc. | 2 | $30 |
| Amgen | 2 | $26 |
| Gilead | 1 | $23 |
| Johnson & Johnson | 1 | $23 |
| Myovant Sciences Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Bayer | 1 | $15 |
| Taiho Oncology, Inc. | 1 | $14 |
| Beigene USA, Inc. | 1 | $14 |
| Puma Biotechnology, Inc. | 1 | $14 |
| Rigel Pharmaceuticals, Inc. | 1 | $13 |
| Karyopharm Therapeutics Inc. | 1 | $13 |
| Global Blood Therapeutics, Inc. | 1 | $12 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
How this compares
$2,703 in reported general payments places this provider in the 50th percentile of 118 hematology & oncology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KisqaliRibociclib Succinate | 38 | $487,474 |
| CalquenceAcalabrutinib Maleate | 30 | $446,529 |
| IbrancePalbociclib | 25 | $398,977 |
| JakafiRuxolitinib Phosphate | 19 | $321,952 |
| Lenalidomide | 21 | $293,937 |
| CabometyxCabozantinib S-Malate | 11 | $282,142 |
| TagrissoOsimertinib Mesylate | 16 | $258,952 |
| RubracaRucaparib Camsylate | 12 | $208,230 |
| ZejulaNiraparib Tosylate | 11 | $200,545 |
| XtandiEnzalutamide | 11 | $155,795 |
| PromactaEltrombopag Olamine | 12 | $147,014 |
| EliquisApixaban | 43 | $38,833 |
| XareltoRivaroxaban | 25 | $21,041 |
| Letrozole | 469 | $12,980 |
| Exemestane | 36 | $11,065 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence, Tagrisso | $88 | $705,48246 claims |
| NovartisKisqali, Promacta | $433 | $634,48850 claims |
| PfizerIbrance, Eliquis | $930 | $437,80968 claims |
| Incyte CorporationJakafi | $56 | $321,95219 claims |
| Astellas Pharma US IncXtandi | $39 | $155,79511 claims |
| Johnson & JohnsonXarelto | $23 | $21,04125 claims |
| AbbVieLinzess | $98 | $6,31812 claims |
| Lilly USA, LLCOlanzapine | $19 | $34522 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 118 hematology & oncology providers in Oklahoma.
Other hematology & oncology in Oklahoma City
- Romeo MandanasOklahoma City$160K
- Mohammad RazaqOklahoma City$56K
- Sami IbrahimiOklahoma City$41K
- Jennifer Holter-ChakrabartyOklahoma City$39K
- Hassan HatoumOklahoma City$23K
- Abdul Rafeh NaqashOklahoma City$23K
- Taha Al-JuhaishiOklahoma City$23K
- Adanma Anji Ayanambakkam AttanathiOklahoma City$16K
- Robert ReynoldsOklahoma City$15K
- Sadia ChohanOklahoma City$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.